Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical, randomised, double-blinded study in which patients eligible for aortic valve replacement are enrolled. Patients receive infusion of either levosimendan or placebo 4 hours prior to surgery and until the end of surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Simendan

Criteria

Inclusion Criteria:

• Eligible for aortic valve replacement

• EF > 45%

• Left ventricular posterior wall > 12mm

• Sinus rhythm

Exclusion Criteria:

• Concomitant bypass operation

• Severe mitral insufficiency

• Active endocarditis

• Insufficient ultrasound opportunity

• Systolic blood pressure < 100 mmHg

• moderate-severe renal failure

• allergy to levosimendan

• lack of patient consent Pregnancy or status of lactating

• Fertile women who do not use relevant anticonception